# Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

> **NCT07489989** · PHASE2 · RECRUITING · sponsor: **Daihong Liu** · enrollment: 30 (estimated)

## Conditions studied

- Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

## Interventions

- **DRUG:** CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance

## Key facts

- **NCT ID:** NCT07489989
- **Lead sponsor:** Daihong Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2027-05-15
- **Final completion:** 2027-05-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489989, "Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07489989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*